1. What Is the Photodynamic Therapy Market?
The Photodynamic Therapy Market covers the cancer and non-cancer treatments that use the combination of the photosensitising agent administered systemically or topically and the activating light at the wavelength specific to the photosensitiser absorption spectrum. The activating light generates the reactive oxygen species in the target tissue that achieves the localised cell killing through the oxidative stress. The singlet oxygen and the free radicals create the oxidative stress in the tumour tissue or the dysplastic tissue that the photosensitiser preferentially accumulates in. PDT applications span the oncological use in the superficial oesophageal, lung endobronchial, bladder, and cholangiocarcinoma treatments. The porfimer sodium and the second-generation photosensitisers temoporfin and aminolevulinic acid ALA and methyl-ALA address these oncological uses. The non-oncological uses include the Barrett's oesophagus ablation, the acne treatment with the ALA topical PDT, and the wet AMD photodynamic therapy with verteporfin that the anti-VEGF treatments have largely displaced. The PDT market is being reinvigorated by the photodynamic diagnosis using the ALA-derived PPIX fluorescence in the bladder and the brain tumour resection. The blue light illumination of the ALA-labelled tumour creates the pink fluorescence that guides the resection of the fluorescent tumour tissue that the white light surgery would leave behind.
2. Photodynamic Therapy Market Size & Forecast
3. Emerging Technologies
- The 5-aminolevulinic acid ALA-mediated fluorescence-guided resection of glioblastoma uses the hexaminolevulinate that accumulates in the malignant glioma and converts to the protoporphyrin IX PPIX. The PPIX fluorescences pink under the blue light illumination during the neurosurgical resection. The technique achieves the 65 versus 36 percent complete resection rate in the PPIX-guided versus white light surgery. The fluorescence advantage in achieving the complete tumour resection correlates with the better progression-free survival.
- PDT for the non-muscle-invasive bladder cancer uses the hexaminolevulinate blue light cystoscopy that improves the detection of the flat carcinoma in situ and the papillary tumours that standard white light cystoscopy misses. The diagnostic PDT application uses the photosensitiser fluorescence. The fluorescence enables the bladder cancer surveillance and the TUR-B resection that removes the bladder tumours identified under both white and blue light.
- Topical ALA and methyl-ALA PDT for the actinic keratosis and the superficial basal cell carcinoma delivers the ALA cream to the lesion and activates with the red light illumination after the photosensitiser incubation period. The technique achieves the 75 to 90 percent complete response rate for the actinic keratosis and the 90 percent for the thin BCC. The daylight PDT and the conventional lamp PDT provide comparable efficacy at the more convenient daylight activation.
- Verteporfin PDT for the wet AMD pathological myopia choroidal neovascularisation treats the disease that anti-VEGF cannot adequately control. The polypoidal choroidal vasculopathy variant benefits particularly from the verteporfin PDT combination with the anti-VEGF. The combination reduces the polyp recurrence rate that the anti-VEGF monotherapy cannot adequately suppress in this AMD subtype.
Similar technologies are also transforming adjacent markets. Learn more in our Radiotherapy Market.
4. Key Market Opportunity
A material opportunity in the Photodynamic Therapy market comes from 5-ALA fluorescence-guided surgery expansion, where increasing evidence supporting fluorescence-guided neurosurgery and potential applications in other cavity-accessible tumours grow the surgical 5-ALA market. Companies with 5-ALA products capturing surgical oncology applications grow beyond the dermatological PDT market. A separate growth lever stems from near-infrared activatable photosensitiser development for deeper tumour PDT. As fluorescence-guided surgery expands and NIR photosensitisers advance, the addressable opportunity is growing from dermatological field treatment and endobronchial PDT toward surgical oncology fluorescence and deeper tumour photodynamic approaches.
5. Top Companies in the Photodynamic Therapy Market
The following organisations hold leading positions in the Photodynamic Therapy Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Biolitec
- Sun Pharma
- Sino Pharmaceutical
- Excel Lasers
- Pinnacle Biologics
- Modulight
- Quest PharmaTech
- Lumibird
- Theralase Technologies
6. Market Segmentation
The Photodynamic Therapy Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Photosensitiser | Porfimer Sodium Aminolevulinic Acid Verteporfin Temoporfin |
| By Application | Skin Cancer Barrett's Oesophagus Endobronchial AMD |
| By Light Source | Laser LED Broadband |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Photodynamic Therapy Market trajectory over the forecast period:
ALA Gliolan Fluorescence-Guided Glioblastoma Resection Achieving 65 vs 36 Percent Complete Resection Versus White Light Surgery in STUPPF Trial Has Established the Pink PPIX Fluorescence as the Neurosurgical Guide That Improves the Complete Resection Rate Correlating With Better Progression-Free Survival.Sun Pharma's Gleolan oral 5-ALA sensitiser produces fluorescent protoporphyrin IX accumulation in glioma cells that allows neurosurgeons to visually distinguish tumour from normal brain tissue under violet light illumination during resection, improving complete resection rates from approximately 33% to 65% in randomised clinical trials. The FDA approval of Gleolan for intraoperative visualisation of malignant glioma tissue based on superior fluorescence-guided complete resection versus standard white-light surgery established a regulatory framework for surgical adjunct drugs that enhance tumour visualization without direct cytotoxic activity. Complete resection of contrast-enhancing tissue is associated with improved progression-free survival in glioblastoma, and the BALANCE trial is evaluating whether 5-ALA-guided supramaximal resection beyond contrast-enhancing boundaries improves survival outcomes compared with standard complete resection.
Hexaminolevulinate Blue Light Cystoscopy Improving Detection of Flat CIS and Papillary Bladder Tumours Missed by White Light Has Established PDT Fluorescence Diagnosis as the Enhanced Surveillance Standard That Improves TUR-B Resection Completeness.QLT's verteporfin photodynamic therapy demonstrated 62% of treated eyes losing fewer than three lines of visual acuity versus 47% of placebo in TAP at one year, establishing the first effective photodynamic treatment for subfoveal choroidal neovascularisation before ranibizumab and bevacizumab's superior efficacy changed practice in 2006. Verteporfin PDT retains a role in polypoidal choroidal vasculopathy where anti-VEGF monotherapy has inferior efficacy, and combination verteporfin plus aflibercept or ranibizumab is being evaluated in PLANET and EVEREST II trials to extend the combination's application in AMD subtypes that anti-VEGF monotherapy does not adequately address. The verteporfin commercial residual after anti-VEGF market disruption demonstrates how photosensitiser therapy can maintain a niche in biomarker-defined patient subsets resistant to the replacing mechanism.
Topical ALA and Methyl-ALA PDT for Actinic Keratosis Achieving 75 to 90 Percent Complete Response With Daylight or Lamp Activation Has Provided the Dermatological Treatment That Field Cancerisation Requires Without the Surgical Excision That Individual Lesion Removal Would Demand.Steba Biotech's padeliporfin WST11 VTP therapy demonstrated 49% of patients with no detectable cancer at biopsy after treatment versus 14% for active surveillance at 2 years in PCM301, establishing the first photodynamic therapy approval for a urological malignancy in Europe. The vascular-targeted mechanism delivers bacteriochlorophyll derivative padeliporfin intravenously and activates it with near-infrared light delivered through interstitial optical fibres within the prostate, generating reactive oxygen species that selectively destroy prostatic vasculature within the illuminated zone. The focal treatment concept addresses the clinical challenge of balancing cancer control with preservation of erectile and urinary function in low-risk prostate cancer, where aggressive whole-gland treatment with surgery or radiotherapy generates toxicity disproportionate to the oncological risk for grade group 1 disease.
For related market intelligence, see the Oncology Drug Market.
8. Segmental Analysis
By photosensitiser, the aminolevulinic-acid-based segment dominated the Photodynamic Therapy Market in 2025, as topical agents from Sun Pharma and Biolitec anchored treatment of actinic keratosis and superficial skin cancers, generating the largest share of photodynamic procedures performed.
By application, the interventional oncology segment is projected to register the highest growth rate through 2034, as fibre-optic light delivery extends photodynamic therapy into bile duct, oesophageal, and lung tumours where minimally invasive ablation offers an alternative to surgery in poor surgical candidates.
9. Regional Analysis
Regional demand patterns across the Photodynamic Therapy Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Photodynamic Therapy Market in 2025, accounting for approximately 46% of global revenue, due to the US dermatology practice with ALA-PDT for actinic keratosis and the 5-ALA fluorescence-guided neurosurgery adoption. Moreover, PDT device and photosensitiser development is concentrated in North American companies. In addition, Barrett's oesophagus PDT sustains demand. Regional dominance is attributed to this combination of dermatological volume and surgical application.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Photodynamic Therapy Market through 2034, driven by the high actinic keratosis burden in sun-exposed European populations and expanding 5-ALA neurosurgery adoption across European brain tumour centres. The region is also witnessing LED-based PDT systems reducing procedure cost. Moreover, next-generation photosensitiser clinical development is active in European academic centres. The combination of these demand drivers and clinical research positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Photodynamic Therapy Market was valued at USD 3.14 Bn in 2025 and is projected to reach USD 6.48 Bn by 2034, growing at a CAGR of 8.4% over the 2026–2034 forecast period.
The Photodynamic Therapy Market is projected to grow at a CAGR of 8.4% from 2026 to 2034.
North America dominated the Photodynamic Therapy Market in 2025, accounting for approximately 46% of global revenue, due to the US dermatology practice with ALA-PDT for actinic keratosis and the 5-ALA fluorescence-guided neurosurgery adoption.
The leading companies in the Photodynamic Therapy Market include Biolitec, Sun Pharma, Sino Pharmaceutical, Excel Lasers, Pinnacle Biologics, Modulight, Quest PharmaTech, Lumibird, Theralase Technologies.
Ala gliolan fluorescence-guided glioblastoma resection achieving 65 vs 36 percent complete resection versus white light surgery in stuppf trial has established the pink ppix fluorescence as the neurosurgical guide that improves the complete resection rate correlating with better progression-free survival.
By photosensitiser, the aminolevulinic-acid-based segment dominated the Photodynamic Therapy Market in 2025, as topical agents from Sun Pharma and Biolitec anchored treatment of actinic keratosis and superficial skin cancers, generating the largest share of photodynamic procedures performed.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.